Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 12-month outcomes of HIV-infected infants identified at birth at one maternity site in Johannesburg, South Africa: an observational cohort study.1 passage
• 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2.1 passage
• A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial.1 passage
• A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study.1 passage
• A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study.1 passage
• A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.1 passage
• AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study.1 passage
• Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study.1 passage
• Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.1 passage
• Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.1 passage
• Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.1 passage
• Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.1 passage
• Adolescent HIV treatment in South Africa's national HIV programme: a retrospective cohort study.1 passage
• Adolescent participation in HIV research: consortium experience in low and middle-income countries and scoping review.1 passage
• Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study.1 passage
• Advanced HIV: diagnosis, treatment, and prevention.1 passage
• Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.1 passage
• Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.1 passage
• Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population-based cohort studies.1 passage
• Age-specific associations between HIV infection and carotid artery intima-media thickness in China: a cross-sectional evaluation of baseline data from the CHART cohort.1 passage
• Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.1 passage
• All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007-14: a retrospective observational cohort study.1 passage
• Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.1 passage
• Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.1 passage
• Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.1 passage
• Application of artificial intelligence and machine learning for HIV prevention interventions.1 passage
• Assisted partner services for HIV in Kenya: a cluster randomised controlled trial.1 passage
• Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.1 passage
• Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis.1 passage
• Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis.1 passage
• Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.1 passage
• Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.1 passage
• Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study.1 passage
• Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in Denmark.1 passage
• Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data.1 passage
• Barriers and strategies to achieve a cure for HIV.1 passage
• Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.1 passage
• Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.1 passage
• Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.1 passage
• Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.1 passage
• Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.1 passage
• Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.1 passage
• Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.1 passage
• Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.1 passage
• Burden of living with HIV among men who have sex with men: a mixed-methods study.1 passage
• CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.1 passage
• CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.1 passage
• Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study.1 passage
• Cancer risk in adolescents and young adults living with HIV in South Africa: a nationwide cohort study.1 passage
• Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.1 passage
• Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action.1 passage
• Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis.1 passage
• Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study.1 passage
• Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.1 passage
• Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.1 passage
• Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.1 passage
• Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial.1 passage
• Cognitive disorders in people living with HIV.1 passage
• Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.1 passage
• Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.1 passage
• Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities.1 passage
• Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study.1 passage
• Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey.1 passage
• Community-based HIV testing services in an urban setting in western Kenya: a programme implementation study.1 passage
• Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17.1 passage
• Community-wide HIV testing, linkage case management, and defaulter tracing in Bukoba, Tanzania: pre-intervention and post-intervention, population-based survey evaluation.1 passage
• Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.1 passage
• Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.1 passage
• Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.1 passage
• Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.1 passage
• Comparison of index-linked HIV testing for children and adolescents in health facility and community settings in Zimbabwe: findings from the interventional B-GAP study.1 passage
• Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).1 passage
• Conditional cash transfers and uptake of and retention in prevention of mother-to-child HIV transmission care: a randomised controlled trial.1 passage
• Conditional economic incentives to improve HIV prevention and treatment in low-income and middle-income countries.1 passage
• Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.1 passage
• Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.1 passage
• Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.1 passage
• Correlates of HIV infection in adolescent girls and young women in Lesotho: results from a population-based survey.1 passage
• Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.1 passage
• Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.1 passage
• Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.1 passage
• Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.1 passage
• Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis.1 passage
• Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.1 passage
• Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.1 passage
• Defining control of HIV epidemics.1 passage
• Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework.1 passage
• Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort.1 passage
• Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study.1 passage
• Development and implementation of participant safety plans for international research with stigmatised populations.1 passage
• Development and validation of an automated HIV prediction algorithm to identify candidates for pre-exposure prophylaxis: a modelling study.1 passage
• Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings.1 passage
• Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland.1 passage
• Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.1 passage
• Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.1 passage
• Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.1 passage
• Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.1 passage
• Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.1 passage
• Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.1 passage
• Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.1 passage
• Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.1 passage
• Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.1 passage
• Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-15: a modelling study.1 passage
• Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?1 passage
• Early infant HIV diagnosis and entry to HIV care cascade in Thailand: an observational study.1 passage
• Economic incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial.1 passage
• Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial.1 passage
• Effect of a clinical decision support system on early action on immunological treatment failure in patients with HIV in Kenya: a cluster randomised controlled trial.1 passage
• Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study.1 passage
• Effect of availability of HIV self-testing on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH): a waiting-list randomised controlled trial.1 passage
• Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.1 passage
• Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study.1 passage
• Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.1 passage
• Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study.1 passage
• Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial.1 passage
• Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study.1 passage
• Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.1 passage
• Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study.1 passage
• Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.1 passage
• Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial.1 passage
• Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.1 passage
• Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity.1 passage
• Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.1 passage
• Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.1 passage
• Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.1 passage
• Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.1 passage
• Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.1 passage
• Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.1 passage
• Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.1 passage
• Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.1 passage
• Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.1 passage
• Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.1 passage
• Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.1 passage
• Efficacy of vitamin D1 passage
• Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.1 passage
• Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.1 passage
• Elimination of HIV transmission through novel and established prevention strategies among people who inject drugs.1 passage
• Ending the HIV epidemic in the USA: an economic modelling study in six cities.1 passage
• Enhanced immigration enforcement in the USA and the transnational continuity of HIV care for Latin American immigrants in deportation proceedings.1 passage
• Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV.1 passage
• Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies.1 passage
• Epidemiology of haematological malignancies in people living with HIV.1 passage
• Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.1 passage
• Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study.1 passage
• Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.1 passage
• Estimation of mortality among HIV-infected people on antiretroviral treatment in East Africa: a sampling based approach in an observational, multisite, cohort study.1 passage
• Ethical considerations in global HIV phylogenetic research.1 passage
• Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial.1 passage
• Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.1 passage
• Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries.1 passage
• Evaluation of the HIV Infant Tracking System (HITSystem) to optimise quality and efficiency of early infant diagnosis: a cluster-randomised trial in Kenya.1 passage
• Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.1 passage
• Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report.1 passage
• Factors associated with HIV infection among children in Larkana District, Pakistan: a matched case-control study.1 passage
• Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.1 passage
• Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations.1 passage
• Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial.1 passage
• Financial incentives to promote retention in care and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial.1 passage
• Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.1 passage
• Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.1 passage
• Framework for the implementation of advanced HIV disease diagnostics in sub-Saharan Africa: programmatic perspectives.1 passage
• From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa.1 passage
• Geographical disparities in HIV prevalence and care among men who have sex with men in Malawi: results from a multisite cross-sectional survey.1 passage
• Global PrEP roll-out: recommendations for programmatic success.1 passage
• Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey.1 passage
• Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries.1 passage
• Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019.1 passage
• Group support psychotherapy for depression treatment in people with HIV/AIDS in northern Uganda: a single-centre randomised controlled trial.1 passage
• Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.1 passage
• Guided internet-based intervention for people with HIV and depressive symptoms: a randomised controlled trial in the Netherlands.1 passage
• HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study.1 passage
• HIV Prevention 2020: a framework for delivery and a call for action.1 passage
• HIV and cardiovascular disease.1 passage
• HIV and the criminalisation of drug use among people who inject drugs: a systematic review.1 passage
• HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study.1 passage
• HIV care continuum in Rwanda: a cross-sectional analysis of the national programme.1 passage
• HIV care continuum interventions for Black men who have sex with men in the USA.1 passage
• HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.1 passage
• HIV controllers: to treat or not to treat? Is that the right question?1 passage
• HIV drug resistance in low-income and middle-income countries.1 passage
• HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use.1 passage
• HIV incidence among people who inject drugs (PWIDs) in Ukraine: results from a clustered randomised trial.1 passage
• HIV incidence in Indigenous and non-Indigenous populations in Australia: a population-level observational study.1 passage
• HIV incidence in western Kenya during scale-up of antiretroviral therapy and voluntary medical male circumcision: a population-based cohort analysis.1 passage
• HIV incidence, pregnancy, and implementation outcomes from the Sakh'umndeni safer conception project in South Africa: a prospective cohort study.1 passage
• HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform.1 passage
• HIV outbreaks among people who inject drugs in Europe, North America, and Israel.1 passage
• HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.1 passage
• HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.1 passage
• HIV prevention cascades: A unifying framework to replicate the successes of treatment cascades.1 passage
• HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis.1 passage
• HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa.1 passage
• HIV transmission and source-sink dynamics in sub-Saharan Africa.1 passage
• HIV transmission networks among transgender women in Los Angeles County, CA, USA: a phylogenetic analysis of surveillance data.1 passage
• HIV treatment in pregnancy.1 passage
• HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.1 passage
• Haemopoietic cell transplantation in patients living with HIV.1 passage
• Harm reduction for smokers living with HIV.1 passage
• Health system adaptations and considerations to facilitate optimal oral pre-exposure prophylaxis scale-up in sub-Saharan Africa.1 passage
• Health systems software factors and their effect on the integration of sexual and reproductive health and HIV services.1 passage
• Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study.1 passage
• Heterogeneity of the HIV epidemic in agrarian, trading, and fishing communities in Rakai, Uganda: an observational epidemiological study.1 passage
• Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.1 passage
• Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial.1 passage
• Household survey of HIV incidence in Rwanda: a national observational cohort study.1 passage
• Hypogonadism and bone health in men with HIV.1 passage
• Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial.1 passage
• Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study.1 passage
• Impact of combination HIV interventions on HIV incidence in hyperendemic fishing communities in Uganda: a prospective cohort study.1 passage
• Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.1 passage
• Implied consent for HIV testing in the UK: time for a new approach?1 passage
• Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012-19): a longitudinal cohort study.1 passage
• Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities.1 passage
• Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study.1 passage
• Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study.1 passage
• Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.1 passage
• Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.1 passage
• Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study.1 passage
• Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.1 passage
• Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies.1 passage
• Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.1 passage
• Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-randomised trial.1 passage
• Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.1 passage
• Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial.1 passage
• Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis.1 passage
• Interventions to strengthen the HIV prevention cascade: a systematic review of reviews.1 passage
• Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.1 passage
• Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.1 passage
• Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz.1 passage
• Key populations and power: people-centred social innovation in Asian HIV services.1 passage
• Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.1 passage
• Linkage to and engagement in HIV care in western Kenya: an observational study using population-based estimates from home-based counselling and testing.1 passage
• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.1 passage
• Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.1 passage
• Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities.1 passage
• Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.1 passage
• Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study.1 passage
• Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.1 passage
• Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study.1 passage
• Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study.1 passage
• Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.1 passage
• Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.1 passage
• Management of active tuberculosis in adults with HIV.1 passage
• Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study.1 passage
• Menopausal hormone therapy for women living with HIV.1 passage
• Messaging matters: achieving equity in the HIV response through public health communication.1 passage
• Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort study.1 passage
• Migration, sexual behaviour, and HIV risk: a general population cohort in rural South Africa.1 passage
• Modern diagnostic technologies for HIV.1 passage
• Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.1 passage
• Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study.1 passage
• Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study.1 passage
• Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study.1 passage
• Mosaic effectiveness: measuring the impact of novel PrEP methods.1 passage
• Moving the HIV vaccine field forward: concepts of protective immunity.1 passage
• Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.1 passage
• Multi-stakeholder consensus on a target product profile for an HIV cure.1 passage
• National estimates and risk factors associated with early mother-to-child transmission of HIV after implementation of option B+: a cross-sectional analysis.1 passage
• National sex work policy and HIV prevalence among sex workers: an ecological regression analysis of 27 European countries.1 passage
• Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.1 passage
• Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.1 passage
• Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study.1 passage
• New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004-15: an analysis of surveillance data.1 passage
• Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance data.1 passage
• Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings.1 passage
• Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.1 passage
• Nurse-led palliative care for HIV-positive patients taking antiretroviral therapy in Kenya: a randomised controlled trial.1 passage
• On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.1 passage
• Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.1 passage
• Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.1 passage
• Optimising treatment in the test-and-treat strategy: what are we waiting for?1 passage
• Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling study.1 passage
• Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.1 passage
• Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study.1 passage
• Overview of SARS-CoV-2 infection in adults living with HIV.1 passage
• Paediatric HIV testing beyond the context of prevention of mother-to-child transmission: a systematic review and meta-analysis.1 passage
• Palliative care as an essential component of the HIV care continuum.1 passage
• Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial.1 passage
• Patient-reported outcomes to enhance person-centred HIV care.1 passage
• Perceived HIV stigma and HIV testing among men and women in rural Uganda: a population-based study.1 passage
• Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis.1 passage
• Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.1 passage
• Phylogenetic inference for the study of within-host HIV-1 dynamics and persistence on antiretroviral therapy.1 passage
• Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.1 passage
• Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial.1 passage
• Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis.1 passage
• Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial.1 passage
• Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.1 passage
• Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.1 passage
• Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.1 passage
• Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study.1 passage
• Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study.1 passage
• PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.1 passage
• PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.1 passage
• Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.1 passage
• Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme.1 passage
• Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study.1 passage
• Pregnancy outcomes in HIV-positive women in Ukraine, 2000-12 (European Collaborative Study in EuroCoord): an observational cohort study.1 passage
• Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.1 passage
• Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.1 passage
• Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis.1 passage
• Prevalence of HIV infection among people with disabilities: a population-based observational study in Yaoundé, Cameroon (HandiVIH).1 passage
• Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study.1 passage
• Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.1 passage
• Primary HIV-1 infection in users of pre-exposure prophylaxis.1 passage
• Prioritising pleasure and correcting misinformation in the era of U=U.1 passage
• Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.1 passage
• Progress of UNAIDS 90-90-90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the HIPSS study: a household-based complex multilevel community survey.1 passage
• Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study.1 passage
• Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-randomised controlled trial.1 passage
• Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.1 passage
• Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua.1 passage
• Providing a conceptual framework for HIV prevention cascades and assessing feasibility of empirical measurement with data from east Zimbabwe: a case study.1 passage
• Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda.1 passage
• Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.1 passage
• Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.1 passage
• Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.1 passage
• Rapid antiretroviral therapy initiation in the Botswana Combination Prevention Project: a quasi-experimental before and after study.1 passage
• Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial.1 passage
• Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis.1 passage
• Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.1 passage
• Recruiting male partners for couple HIV testing and counselling in Malawi's option B+ programme: an unblinded randomised controlled trial.1 passage
• Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.1 passage
• Reliability of HIV rapid diagnostic tests for self-testing compared with testing by health-care workers: a systematic review and meta-analysis.1 passage
• Reorienting health systems to care for people with HIV beyond viral suppression.1 passage
• Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study.1 passage
• Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.1 passage
• Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study.1 passage
• Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.1 passage
• Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.1 passage
• SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.1 passage
• Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.1 passage
• Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.1 passage
• Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.1 passage
• Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.1 passage
• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.1 passage
• Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.1 passage
• Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.1 passage
• Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.1 passage
• Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.1 passage
• Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.1 passage
• Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.1 passage
• Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.1 passage
• Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial.1 passage
• Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.1 passage
• Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.1 passage
• Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention.1 passage
• Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study.1 passage
• Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis.1 passage
• Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study.1 passage
• Sexual behaviours, HIV testing, and the proportion of men at risk of transmitting and acquiring HIV in London, UK, 2000-13: a serial cross-sectional study.1 passage
• Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.1 passage
• Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.1 passage
• Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.1 passage
• Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.1 passage
• Sources of racial disparities in HIV prevalence in men who have sex with men in Atlanta, GA, USA: a modelling study.1 passage
• Stigma reduction interventions in people living with HIV to improve health-related quality of life.1 passage
• Stigma reduction: an essential ingredient to ending AIDS by 2030.1 passage
• Strategies for engaging men in HIV services.1 passage
• Strengthening measurement and performance of HIV prevention programmes.1 passage
• Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study.1 passage
• Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.1 passage
• Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.1 passage
• Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study.1 passage
• Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.1 passage
• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.1 passage
• Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.1 passage
• Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.1 passage
• Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials.1 passage
• Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial.1 passage
• Temporal change in population-level prevalence of detectable HIV viraemia and its association with HIV incidence in key populations in India: a serial cross-sectional study.1 passage
• Temporal trends in HIV-1 incidence and risk behaviours in men who have sex with men in Bangkok, Thailand, 2006-13: an observational study.1 passage
• Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.1 passage
• Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.1 passage
• Testing and linkage to HIV care in China: a cluster-randomised trial.1 passage
• The Amagugu intervention for disclosure of maternal HIV to uninfected primary school-aged children in South Africa: a randomised controlled trial.1 passage
• The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring.1 passage
• The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV.1 passage
• The HOPE social media intervention for global HIV prevention in Peru: a cluster randomised controlled trial.1 passage
• The Spear and Shield intervention to increase the availability and acceptability of voluntary medical male circumcision in Zambia: a cluster randomised controlled trial.1 passage
• The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.1 passage
• The cascade of HIV care among key populations in Indonesia: a prospective cohort study.1 passage
• The case for an HIV cure and how to get there.1 passage
• The case for prescribing PrEP in community mental health settings.1 passage
• The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment.1 passage
• The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study.1 passage
• The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.1 passage
• The effect of providing women sustained access to HIV self-tests on male partner testing, couples testing, and HIV incidence in Kenya: a cluster-randomised trial.1 passage
• The finding of casual sex partners on the internet, methamphetamine use for sexual pleasure, and incidence of HIV infection among men who have sex with men in Bangkok, Thailand: an observational cohort study.1 passage
• The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS.1 passage
• The immediate eff ect of the Same-Sex Marriage Prohibition Act on stigma, discrimination, and engagement on HIV prevention and treatment services in men who have sex with men in Nigeria: analysis of prospective data from the TRUST cohort.1 passage
• The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis.1 passage
• The last Black man with HIV in San Francisco: the potential role of gentrification on HIV getting to zero achievements.1 passage
• The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study.1 passage
• The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study.1 passage
• The potential impact of country-level migration networks on HIV epidemics in sub-Saharan Africa: the case of Botswana.1 passage
• The usefulness of HIV partner services in the age of treatment as prevention: a registry-based study.1 passage
• Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.1 passage
• Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study.1 passage
• Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis.1 passage
• Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study.1 passage
• Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study.1 passage
• Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000-20: a modelling study using survey and HIV testing programme data.1 passage
• Trends in post-partum viral load among women living with perinatal HIV infection in the USA: a prospective cohort study.1 passage
• Trends in the burden of HIV mortality after roll-out of antiretroviral therapy in KwaZulu-Natal, South Africa: an observational community cohort study.1 passage
• Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.1 passage
• Understanding HIV risk and vulnerability among cisgender men with transgender partners.1 passage
• Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.1 passage
• Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study.1 passage
• Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil.1 passage
• Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.1 passage
• Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.1 passage
• Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.1 passage
• Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV-infected children in Kenya (PUSH): a randomised controlled trial.1 passage
• Use of electronic health record data and machine learning to identify candidates for HIV pre-exposure prophylaxis: a modelling study.1 passage
• Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006-17): a retrospective cohort study.1 passage
• Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.1 passage
• Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden.1 passage
• Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study.1 passage
• Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial.1 passage
• Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.1 passage
• Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.1 passage
• Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.1 passage
• Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study.1 passage